A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.

Trial Details

NCT ID
NCT06663319
Phase
PHASE1
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • JNJ-89402638
  • Bevacizumab
  • FOLFOX
  • FOLFIRI
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Grand Rapids, Michigan, United States|42.96336,-85.66809

Key Eligibility Criteria

  • For Part 1 (dose escalation), Part 2 (Arm A \[JNJ-89402638 monotherapy\]): Have histologically or cytologically confirmed diagnosis of colorectal a…
  • Have evaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) version 1.1
  • Part 1: Must have either measurable or evaluable disease
  • Part 2: Must have at least 1 measurable lesion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →